Liposomal formulations for lung cancer treatment in the last two decades: a systematic review
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | https://hdl.handle.net/1822/79332 |
Resumo: | Purpose Lung cancer is the leading cause of cancer mortality worldwide. To improve the therapeutic outcomes, drug delivery systems, and particularly liposomes, have been widely investigated. Therefore, this review analyzed systematically the literature to inquire about the safety and efcacy of liposomal formulations in lung cancer treatment. Methods Three electronic databases (PubMed, Web of Science and Cochrane CENTRAL) were systematically searched until May 2020. Clinical trials containing information about the efects of liposomal formulations in lung cancer patients were considered eligible. Results Twenty two selected studies present diferent treatment options for both small and non-small-cell lung cancers. After compiling and analyzing all the published information, we verifed that combination of liposomal cisplatin and paclitaxel led to a statistically signifcant improvement of the evaluated outcomes. Moreover, tecemotide, a liposome-based immunotherapy, demonstrated lower toxicity compared to control groups. Evidences that other subgroups could beneft from this formulation were also provided. Conclusion This systematic review (registration number CRD42021246587) demonstrates that liposomal formulations are promising alternatives to overcome limitations of traditional cancer therapy. However, larger, longer, randomized and double-blinded clinical trials, selecting their patientsâ cohort considering more responsive subgroups would be benefcial to strengthen the scientifc and clinical evidence of the results herein reported. |
id |
RCAP_ce316c9030ad6c4d4dc825f839b7cf7b |
---|---|
oai_identifier_str |
oai:repositorium.sdum.uminho.pt:1822/79332 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Liposomal formulations for lung cancer treatment in the last two decades: a systematic reviewAdverse eventsClinical trialsDrug deliveryEfficacyLiposomal formulationsLung cancerScience & TechnologyPurpose Lung cancer is the leading cause of cancer mortality worldwide. To improve the therapeutic outcomes, drug delivery systems, and particularly liposomes, have been widely investigated. Therefore, this review analyzed systematically the literature to inquire about the safety and efcacy of liposomal formulations in lung cancer treatment. Methods Three electronic databases (PubMed, Web of Science and Cochrane CENTRAL) were systematically searched until May 2020. Clinical trials containing information about the efects of liposomal formulations in lung cancer patients were considered eligible. Results Twenty two selected studies present diferent treatment options for both small and non-small-cell lung cancers. After compiling and analyzing all the published information, we verifed that combination of liposomal cisplatin and paclitaxel led to a statistically signifcant improvement of the evaluated outcomes. Moreover, tecemotide, a liposome-based immunotherapy, demonstrated lower toxicity compared to control groups. Evidences that other subgroups could beneft from this formulation were also provided. Conclusion This systematic review (registration number CRD42021246587) demonstrates that liposomal formulations are promising alternatives to overcome limitations of traditional cancer therapy. However, larger, longer, randomized and double-blinded clinical trials, selecting their patientsâ cohort considering more responsive subgroups would be benefcial to strengthen the scientifc and clinical evidence of the results herein reported.SpringerUniversidade do MinhoCanão, FilipaFerreira, HelenaNeves, N. M.2022-062022-06-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/1822/79332engCanão F., Ferreira H., Neves N. M. Liposomal formulations for lung cancer treatment in the last two decades: a systematic review, Journal of Cancer Research and Clinical Oncology , Vol. 148, pp. 2375-2386, doi:10.1007/s00432-022-04079-x, 20221432-133510.1007/s00432-022-04079-x35660950https://doi.org/10.1007/s00432-022-04079-xinfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-21T12:30:29Zoai:repositorium.sdum.uminho.pt:1822/79332Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T19:25:40.843191Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Liposomal formulations for lung cancer treatment in the last two decades: a systematic review |
title |
Liposomal formulations for lung cancer treatment in the last two decades: a systematic review |
spellingShingle |
Liposomal formulations for lung cancer treatment in the last two decades: a systematic review Canão, Filipa Adverse events Clinical trials Drug delivery Efficacy Liposomal formulations Lung cancer Science & Technology |
title_short |
Liposomal formulations for lung cancer treatment in the last two decades: a systematic review |
title_full |
Liposomal formulations for lung cancer treatment in the last two decades: a systematic review |
title_fullStr |
Liposomal formulations for lung cancer treatment in the last two decades: a systematic review |
title_full_unstemmed |
Liposomal formulations for lung cancer treatment in the last two decades: a systematic review |
title_sort |
Liposomal formulations for lung cancer treatment in the last two decades: a systematic review |
author |
Canão, Filipa |
author_facet |
Canão, Filipa Ferreira, Helena Neves, N. M. |
author_role |
author |
author2 |
Ferreira, Helena Neves, N. M. |
author2_role |
author author |
dc.contributor.none.fl_str_mv |
Universidade do Minho |
dc.contributor.author.fl_str_mv |
Canão, Filipa Ferreira, Helena Neves, N. M. |
dc.subject.por.fl_str_mv |
Adverse events Clinical trials Drug delivery Efficacy Liposomal formulations Lung cancer Science & Technology |
topic |
Adverse events Clinical trials Drug delivery Efficacy Liposomal formulations Lung cancer Science & Technology |
description |
Purpose Lung cancer is the leading cause of cancer mortality worldwide. To improve the therapeutic outcomes, drug delivery systems, and particularly liposomes, have been widely investigated. Therefore, this review analyzed systematically the literature to inquire about the safety and efcacy of liposomal formulations in lung cancer treatment. Methods Three electronic databases (PubMed, Web of Science and Cochrane CENTRAL) were systematically searched until May 2020. Clinical trials containing information about the efects of liposomal formulations in lung cancer patients were considered eligible. Results Twenty two selected studies present diferent treatment options for both small and non-small-cell lung cancers. After compiling and analyzing all the published information, we verifed that combination of liposomal cisplatin and paclitaxel led to a statistically signifcant improvement of the evaluated outcomes. Moreover, tecemotide, a liposome-based immunotherapy, demonstrated lower toxicity compared to control groups. Evidences that other subgroups could beneft from this formulation were also provided. Conclusion This systematic review (registration number CRD42021246587) demonstrates that liposomal formulations are promising alternatives to overcome limitations of traditional cancer therapy. However, larger, longer, randomized and double-blinded clinical trials, selecting their patientsâ cohort considering more responsive subgroups would be benefcial to strengthen the scientifc and clinical evidence of the results herein reported. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-06 2022-06-01T00:00:00Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://hdl.handle.net/1822/79332 |
url |
https://hdl.handle.net/1822/79332 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Canão F., Ferreira H., Neves N. M. Liposomal formulations for lung cancer treatment in the last two decades: a systematic review, Journal of Cancer Research and Clinical Oncology , Vol. 148, pp. 2375-2386, doi:10.1007/s00432-022-04079-x, 2022 1432-1335 10.1007/s00432-022-04079-x 35660950 https://doi.org/10.1007/s00432-022-04079-x |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Springer |
publisher.none.fl_str_mv |
Springer |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799132742038847488 |